Casdin Capital, an investment company, led a $160m Series C funding round in Century Therapeutics, a cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology. Additional investors include Fidelity Management & Research, the Federated Hermes Kauffmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, and Octagon Capital, Versant Ventures and Leaps by Bayer. "We are fortunate to be surrounded by such a top-tier group of investors, whose support will enable the acceleration of Century's technology platform into the clinic. With this new investor partnership, we are well-positioned to capitalize on the tremendous potential of our integrated iPSC, cell engineering and manufacturing capabilities to develop safer, more effective and more affordable next generation allogeneic cancer therapies," Lalo Flores, Century Therapeutics CEO.